Table 1 Demographics of patients underwent biopsy followed by prostatectomy in total and subgroups

Age at biopsy (year), M(IQR)

67.0(63.0–71.0)

67.0 (62.0–71.0)

67.0 (63.0–71.0)

0.496^a

MS (n, %)

–

–

–

0.150

 Absence

156(78.8)

66 (74.2)

90 (82.6)

–

 Presence

42(21.2)

23 (25.8)

19 (17.4)

–

BMI, M(IQR) (kg/m²)

24.7(22.9–26.9)

25.0(23.1–27.2)

24.6(22.3–26.7)

0.345^a

Interval from biopsy to RP, M(IQR) (d)

21.0(14.0–34.3)

21.0(14.0–31.5)

21.0(14.0–35.0)

0.771^b

PV, M(IQR) (ml)

39.0(28.1–53.0)

38.8(28.7–52.8)

39.2(23.9–53.4)

0.801^b

Pre-biopsy PSA level, M(IQR) (ng/ml)

14.2(8.6–28.7)

15.7(9.1–35.9)

13.1(7.8–23.6)

0.032^b

Pre-biopsy PSAD, M(IQR) (ng/ml²)

0.37(0.21–0.79)

0.46(0.23–1.01)

0.34(0.20–0.74)

0.061^b

Clinical T-stage (n, %)

–

–

–

0.002

 T_1c-2a

63(31.8)

18 (20.2)

45 (41.3)

0.001^c

 T_2b-2c

105(53.0)

59 (66.3)

46 (42.2)

0.117^d

 T_3a-3b

30(15.2)

12(13.5)

18 (16.5)

0.270^e

PI-RADS score (n, %)

–

–

–

< 0.001

 2–3

51(25.8)

9 (10.1)

42 (38.5)

–

 4–5

147(74.2)

80 (89.9)

67 (61.5)

–

Cores obtained (n, %)

–

–

–

0.480

 12–23

16(8.1)

9(10.1)

7(6.4)

–

 24

165(83.3)

74(83.1)

91(83.5)

–

 25–30

17(8.6)

6(6.7)

11(10.1)

–

FPC, M(IQR) (%)

25.0(13.0–42.0)

25.0(12.5–48.0)

25.0(13.0–42.0)

0.906^b

GPC, M(IQR) (%)

70.0(30.0–90.0)

90.0(50.0–90.0)

50.0(30.0–90.0)

0.001^b

Experience in biopsy (n, %)

–

–

–

0.886

 Senior

79(39.9)

36(40.4)

43 (39.4)

–

 Junior

119(60.1)

53 (59.6)

66 (60.6)

–